virbamec vet 10 mg/ml injektioneste, liuos
virbac - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini
noromectin pour-on vet 5 mg/ml kertavaleluliuos
norbrook laboratories (ireland) limited - ivermectin - kertavaleluliuos - 5 mg/ml - ivermektiini
bimectin vet 10 mg/ml injektioneste, liuos
bimeda animal health limited - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini
animec vet 10 mg/ml injektioneste, liuos
chanelle pharmaceuticals manufacturing limited - ivermectin - injektioneste, liuos - 10 mg/ml - ivermektiini
butox vet 7.5 mg/ml kertavalelususpensio
intervet international b.v. - deltamethrin - kertavalelususpensio - 7.5 mg/ml - deltametriini
neoprinil pour-on 5 mg/ml kertavaleluliuos
virbac - eprinomectin - kertavaleluliuos - 5 mg/ml - eprinomektiini
dectospot vet 10 mg/ml kertavaleluliuos
bimeda animal health limited - deltamethrin - kertavaleluliuos - 10 mg/ml - deltametriini
eprinex vet. 5 mg/ml kertavaleluliuos
boehringer ingelheim animal health nordics a/s - eprinomectin - kertavaleluliuos - 5 mg/ml - eprinomektiini
longrange
merial - eprinomectin - endektosidit - karja - hoitoa seuraavien loisten:ruoansulatuskanavan sukkulamadot (täysikasvuiset ja l4):- ostertagia ostertagi/lyrata, cooperia oncophora/surnabada, c. punctata, haemonchus contortus, trichostrongylus axel, t. colubriformis, bunostomum phlebotomum, nematodirus helvetianus, oesophagostomum radiatumlungworm (aikuiset ja l4):- dictyocaulus viviparuswarbles (lois-vaiheet):- hypoderma bovis, s. lineatummange punkit:- sarcoptes scabiei var. bovis täitä: linognathus vituli, haematopinus eurysternus, solenoptes capillatushorn lentää: haematobia irritansprevention ja reinfections seuraavat parasiitit:- dictyocaulus viviparus, ostertagia ostertagi/lyrata, trichostrongylus colubriformis, haemonchus contortus, ja bunostomum phlebotomum;- oesophagostomum radiatum, cooperia oncophora/surnabada, c. punctata ja trichostrongylus axel.
vidaza
bristol-myers squibb pharma eeig - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.